Shares of Treace Medical Concepts Inc. (NASDAQ: TMCI) surged 18.07% in pre-market trading on Friday, following the company's impressive fourth-quarter results and optimistic outlook for 2025. The medical device company, specializing in bunion treatments, reported a strong revenue growth and introduced several new products aimed at addressing different classes of bunion deformities.

In the fourth quarter of 2024, Treace Medical Concepts reported revenue of $68.7 million, representing a 10.4% increase compared to the same period in the previous year. For the full year 2024, the company's revenue grew by 12% to $209.4 million, driven by increased adoption of its flagship Lapiplasty system and other complementary products.

The company's success can be attributed to its comprehensive approach to bunion treatment. With a growing base of over 3,100 surgeon customers, Treace Medical Concepts has introduced several new products, including the nanoplasty and percuplasty systems for minimally invasive osteotomies, as well as solutions for midfoot deformities and arthritic great toe joints.

CEO John Treace expressed excitement about the positive early feedback received on the new products, which have been refined over several years. He believes the expanded portfolio will not only reinforce the company's position with its existing customer base but also attract new surgeons seeking specialized solutions for various bunion classes.

For the full year 2025, Treace Medical Concepts has provided revenue guidance of $224 million to $230 million, reflecting an expected increase of 7% to 10% over 2024. The company also expects to achieve break-even adjusted EBITDA in 2025, indicating its focus on profitability.